Found: 11
Select item for more details and to access through your institution.
Clinical Impact of Pitolisant on Excessive Daytime Sleepiness and Cataplexy in Adults With Narcolepsy: An Analysis of Randomized Placebo-Controlled Trials.
- Published in:
- CNS Drugs, 2022, v. 36, n. 1, p. 61, doi. 10.1007/s40263-021-00886-x
- By:
- Publication type:
- Article
Correction to: Nusinersen: A Review in 5q Spinal Muscular Atrophy.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Multiple Sclerosis in Children: Differential Diagnosis, Prognosis, and Disease-Modifying Treatment.
- Published in:
- CNS Drugs, 2022, v. 36, n. 1, p. 45, doi. 10.1007/s40263-021-00887-w
- By:
- Publication type:
- Article
Kalirin as a Novel Treatment Target for Cognitive Dysfunction in Schizophrenia.
- Published in:
- CNS Drugs, 2022, v. 36, n. 1, p. 1, doi. 10.1007/s40263-021-00884-z
- By:
- Publication type:
- Article
Authors' Reply to Ulrich: Comment on 'Monoamine Oxidase Inhibitors (MAOIs) in Psychiatric Practice: How to Use Them Safely and Effectively'.
- Published in:
- 2022
- By:
- Publication type:
- Letter
Comment on: "Monoamine Oxidase Inhibitors (MAOIs) in Psychiatric Practice: How to Use them Safely and Effectively".
- Published in:
- 2022
- By:
- Publication type:
- Letter
Correction to: Monoamine Oxidase Inhibitors (MAOIs) in Psychiatric Practice: How to Use them Safely and Effectively.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Cannabis-Based Medicines and Medical Cannabis for Chronic Neuropathic Pain.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Molecular Mechanisms of Psilocybin and Implications for the Treatment of Depression.
- Published in:
- CNS Drugs, 2022, v. 36, n. 1, p. 17, doi. 10.1007/s40263-021-00877-y
- By:
- Publication type:
- Article
Pharmacokinetics, Safety, and Tolerability of SHP465 Mixed Amphetamine Salts After Administration of Multiple Daily Doses in Children Aged 4–5 Years with Attention-Deficit/Hyperactivity Disorder.
- Published in:
- CNS Drugs, 2022, v. 36, n. 1, p. 71, doi. 10.1007/s40263-021-00870-5
- By:
- Publication type:
- Article
Impact of Natural Killer (NK) Cells on Immune Reconstitution, and Their Potential as a Biomarker of Disease Activity, in Alemtuzumab-Treated Patients with Relapsing Remitting Multiple Sclerosis: An Observational Study.
- Published in:
- CNS Drugs, 2022, v. 36, n. 1, p. 83, doi. 10.1007/s40263-021-00875-0
- By:
- Publication type:
- Article